Objective:To explore the clinical efficacy of modified Dingxianwan combined with levetiracetam on syndrome of phlegm-fire disturbing mind in children with epilepsy. Method:The 114 children with epilepsy of phlegm-fire disturbing mind type admitted in our hospital from September 2015 to September 2017

were evenly divided into two groups on the basis of random number table. The patients in control group (57 cases) were given with levetiracetam tablets orally

while the patients in observation group (57 cases) received modified Dingxianwan in addition to what was applied to control group. All children from the two groups were treated for 6 months. The clinical efficacy

changes of Chinese revised Wechsler Intelligence Scale for children (C-WISC) and the Quality of Life in Childhood Epilepsy (QOLCE) scores before and after treatment

and adverse reactions

interleukin-6 (IL-6)

interleukin-1β(IL-1β)

tumor necrosis factor-α (TNF-α)

and superoxide dismutase (SOD)

reduced glutathione(GSH)

glutathione peroxidase (GSH-Px) and malondialdehyde (MDA) levels were detected and compared between two groups. Result:After 6 months of treatment

the overall effective rate was 93.0% (53/57) in observation group

much higher than 77.2% (44/57) in control group (χ2=5.600

P<0.05). After treatment

both groups showed a remarkable increase in scores for their intellectual function[performance intelligence quotient (PIQ)

verbal intelligence quotient (VIQ)]and full intelligence quotient (FIQ) as compared with those before treatment (P<0.05)

and the increase in observation group was more obvious (P<0.05). As compared with those before treatment

the scores for all QOLCE dimensions (including physical function

emotional well-being

and behavioral function

etc.)

general health

self-rating life quality

and the total score for QOLCE were obviously increased in both groups after treatment (P<0.05)

and observation group showed a more significant increase (P<0.05). As compared with control group[5.3%(3/57)]

the adverse reaction rate was 8.8% (5/57) in observation group

with no statistically significant difference. The levels of IL-6

IL-1β

TNF-α and MDA in observation group were lower than those in control group (P<0.05); the levels of serum SOD

GSH

and GSH-Px were higher than those in control group (P<0.05). Conclusion:In treating children with epilepsy (syndrome of phlegm-fire disturbing mind)

the combination of modified Dingxianwan and levetiracetam can significantly relieve the symptom in the children

mitigate epileptic seizures

and improve cognitive function and life quality

proving to be effective and safe.